NO168086C - Fremgangsmaate for fremstilling av en stabilisert, vandig insulinopploesning - Google Patents

Fremgangsmaate for fremstilling av en stabilisert, vandig insulinopploesning

Info

Publication number
NO168086C
NO168086C NO823603A NO823603A NO168086C NO 168086 C NO168086 C NO 168086C NO 823603 A NO823603 A NO 823603A NO 823603 A NO823603 A NO 823603A NO 168086 C NO168086 C NO 168086C
Authority
NO
Norway
Prior art keywords
preparing
procedure
insulin solution
stabilized aqueous
aqueous insulin
Prior art date
Application number
NO823603A
Other languages
English (en)
Norwegian (no)
Other versions
NO823603L (no
NO168086B (no
Inventor
Philip Edgar Hansen
Jens Joergen Vejlgaard Brange
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO823603L publication Critical patent/NO823603L/no
Publication of NO168086B publication Critical patent/NO168086B/no
Publication of NO168086C publication Critical patent/NO168086C/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
NO823603A 1981-10-30 1982-10-29 Fremgangsmaate for fremstilling av en stabilisert, vandig insulinopploesning NO168086C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK478681 1981-10-30
DK324782 1982-07-20

Publications (3)

Publication Number Publication Date
NO823603L NO823603L (no) 1983-05-02
NO168086B NO168086B (no) 1991-10-07
NO168086C true NO168086C (no) 1992-01-15

Family

ID=26066963

Family Applications (1)

Application Number Title Priority Date Filing Date
NO823603A NO168086C (no) 1981-10-30 1982-10-29 Fremgangsmaate for fremstilling av en stabilisert, vandig insulinopploesning

Country Status (20)

Country Link
US (1) US4614730A (lt)
AT (1) AT382079B (lt)
AU (1) AU549593B2 (lt)
BE (1) BE894885A (lt)
CA (1) CA1198673A (lt)
CH (1) CH649922A5 (lt)
DE (1) DE3240177A1 (lt)
ES (1) ES516963A0 (lt)
FI (1) FI80595C (lt)
FR (1) FR2515517B1 (lt)
GB (1) GB2107985B (lt)
GR (1) GR77360B (lt)
IE (1) IE54029B1 (lt)
IT (1) IT1153315B (lt)
LU (1) LU84447A1 (lt)
NL (1) NL193099C (lt)
NO (1) NO168086C (lt)
NZ (1) NZ202328A (lt)
PT (1) PT75766B (lt)
SE (1) SE460576B (lt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
US4914084A (en) * 1984-05-09 1990-04-03 Synthetic Blood Corporation Composition and method for introducing heme, hemoproteins, and/or heme-hemoprotein complexes into the body
WO1985005029A1 (en) * 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
DE3443877A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
FR2605449B1 (fr) * 1986-10-17 1988-12-02 Thomson Cgr Bloc magnetique a aimantation ajustable pour la production d'un champ magnetique permanent dans une zone d'interet
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5725871A (en) * 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
AU663683B2 (en) * 1990-04-17 1995-10-19 Analytical Control Systems, Inc. Coagulation assays and reagents
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
AU689217B2 (en) 1994-03-07 1998-03-26 Novartis Ag Methods and compositions for pulmonary delivery of insulin
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
ES2360182T3 (es) 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
CN104001159B (zh) 2010-07-14 2016-08-24 中国医学科学院药物研究所 一种胰岛素的脂质复合物及其制备方法和制剂
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2685962A1 (en) 2011-03-17 2014-01-22 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
WO2018109162A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US20200197357A1 (en) 2017-07-20 2020-06-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods of lipophilic drugs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2563070A (en) * 1947-12-19 1951-08-07 Chicago Medical School Antidiabetic
GB1285023A (en) * 1968-08-09 1972-08-09 Novo Terapeutisk Labor As Improvements in or relating to injectable insulin preparations
US3758683A (en) * 1971-04-30 1973-09-11 R Jackson Insulin product
JPS50116028A (lt) * 1974-02-26 1975-09-11
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
US4164573A (en) * 1975-06-13 1979-08-14 Galinsky Alvin M Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
CH621479A5 (lt) * 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (lt) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
DE2952119A1 (de) * 1979-12-22 1981-07-09 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige protein-loesungen
EP0032622B1 (en) * 1979-12-20 1985-08-14 Dennis Chapman Polymerisable phospholipids and polymers thereof, methods for their preparation, methods for their use in coating substrates and forming liposomes and the resulting coated substrates and liposome compositions

Also Published As

Publication number Publication date
FI823702A0 (fi) 1982-10-29
GB2107985A (en) 1983-05-11
GR77360B (lt) 1984-09-11
PT75766B (en) 1985-12-09
BE894885A (fr) 1983-04-29
US4614730A (en) 1986-09-30
NL8203944A (nl) 1983-05-16
FI80595C (fi) 1990-07-10
LU84447A1 (fr) 1983-06-13
ES8403025A1 (es) 1984-03-01
IE54029B1 (en) 1989-05-24
ATA392482A (de) 1986-06-15
FI823702L (fi) 1983-05-01
IT8223990A0 (it) 1982-10-29
DE3240177A1 (de) 1983-05-11
AT382079B (de) 1987-01-12
IT1153315B (it) 1987-01-14
NO823603L (no) 1983-05-02
AU549593B2 (en) 1986-01-30
FI80595B (fi) 1990-03-30
ES516963A0 (es) 1984-03-01
NL193099B (nl) 1998-07-01
SE8206168D0 (sv) 1982-10-29
CH649922A5 (de) 1985-06-28
IE822602L (en) 1983-04-30
FR2515517B1 (fr) 1987-07-03
FR2515517A1 (fr) 1983-05-06
GB2107985B (en) 1984-11-14
NL193099C (nl) 1998-11-03
CA1198673A (en) 1985-12-31
PT75766A (en) 1982-11-01
AU8986182A (en) 1983-05-05
NO168086B (no) 1991-10-07
SE8206168L (sv) 1983-05-01
NZ202328A (en) 1985-07-12
SE460576B (sv) 1989-10-30
DE3240177C2 (lt) 1993-07-22

Similar Documents

Publication Publication Date Title
NO168086C (no) Fremgangsmaate for fremstilling av en stabilisert, vandig insulinopploesning
NO874347D0 (no) Fremgangsmaate for fremstilling av insulin.
AR223983A1 (es) Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
NO864368L (no) Fremgangsmaate for fremstilling av et vaskepulver.
ES519031A0 (es) Un procedimiento para preparar derivados de fenilciclobutano.
ES509449A0 (es) "un procedimiento de preparacion de derivados de 1,3-dihidro-6-metil-7-hidroxi-furo-3,4-c-piridina".
NO160526C (no) Fremgangsmaate for fremstilling av en forbindelse som omfatter en 1,2-dihydroksy-cykloheksa-3,5-dienring.
ES520249A0 (es) Procedimiento de producir preparaciones de insulina.
ES516133A0 (es) Un procedimiento de preparacion de un compuesto.
NO822704L (no) Fremgangsmaate for fremstilling av insulinderivater.
ES517459A0 (es) Un procedimiento para preparar un dentifrico estable.
NO162669C (no) Fremgangsmaate for fremstilling av en hgprt-manglende human-t-leukemi cellelinje.
NO153916C (no) Fremgangsmaate for fremstilling av en stabil, injiserbar opploesning av et oksytetracyklinchelat.
ES510654A0 (es) Un procedimiento para la preparacion de derivados de 1,1-dioxido del acido penicilanico.
ES527304A0 (es) Un procedimiento para preparar derivados de pirimidona.
IT1206106B (it) Procedimento per preparare penemderivati otticamente attivi.
RO81951A (ro) Procedeu de preparare a unui precursor de insulina
FI824135A0 (fi) Foerfarande foer separering av blandningar av insulin, insulinderivat och eventuella foeroreningar
ES508928A0 (es) Un procedimiento para preparar derivados de n-acil-n-hidroxi-a minoacidos.
ES514057A0 (es) "un procedimiento para preparar un 1,4-dialcohilo inferior-3-alcoxicarbonilo inferior-pirrol-2-acetato de alcohilo inferior".
ES521598A0 (es) Procedimiento de preparar derivados piridotienopiridacinicos.
IT1155373B (it) Procedimento di preparazione di derivati para-chinonici o orto-chinonici, eventualmente alcossilati o arilossilati, rispettivamente a partire dai derivati idrochinonici o pirocatechici corrispondenti
NO155428C (no) Fremgangsmaate for fremstilling av en stabil loesning av hydrogenerte ergotalkaloider.
DK149833C (da) Fremgangsmaade til fremstilling af et oploest zinkinsulinpraeparat, derer fysisk stabilt
DK152832C (da) Fremgangsmaade til fremstilling af en vandig insulinoploesning, der er fysisk stabiliseret mod graensefladepolymerisation